Stockscreener 앱 받기
87.06
0.23%
0.20
시간 외 거래:
87.00
-0.06
-0.07%
전일 마감가:
$86.86
열려 있는:
$86.19
하루 거래량:
1.08M
Relative Volume:
0.89
시가총액:
$21.87B
수익:
$3.26B
순이익/손실:
$-1.45B
주가수익비율:
-14.83
EPS:
-5.871
순현금흐름:
$1.18B
1주 성능:
-4.51%
1개월 성능:
-11.63%
6개월 성능:
-14.70%
1년 성능:
-17.91%
1일 변동 폭
$85.00
$87.27
1주일 범위
$85.00
$92.73
52주 변동 폭
$79.52
$124.00
바이오앤테크 Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
87.06 | 21.87B | 3.26B | -1.45B | 1.18B | -5.871 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
바이오앤테크 Stock (BNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-08 | 개시 | Argus | Hold |
| 2026-09-08 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2026-05-27 | 업그레이드 | UBS | Neutral → Buy |
| 2026-05-22 | 개시 | Bernstein | Mkt Perform |
| 2026-02-02 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-06-05 | 재확인 | H.C. Wainwright | Buy |
| 2025-05-29 | 개시 | Goldman | Neutral |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-01-10 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-11-19 | 개시 | Berenberg | Buy |
| 2024-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-09-24 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-08-02 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-14 | 개시 | Evercore ISI | In-line |
| 2024-02-23 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-05 | 개시 | Oppenheimer | Perform |
| 2023-12-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-10-16 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-17 | 업그레이드 | Redburn | Neutral → Buy |
| 2022-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-08-17 | 개시 | Cowen | Market Perform |
| 2022-07-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2021-12-16 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-08-11 | 업그레이드 | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-16 | 다운그레이드 | Redburn | Neutral → Sell |
| 2021-05-18 | 개시 | Goldman | Neutral |
| 2021-05-11 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-08-03 | 재개 | Berenberg | Buy |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-06-30 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-03-09 | 개시 | H.C. Wainwright | Neutral |
| 2020-01-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-11-05 | 개시 | Wolfe Research | Outperform |
| 2019-11-04 | 개시 | Berenberg | Buy |
| 2019-11-04 | 개시 | BofA/Merrill | Buy |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-11-04 | 개시 | JP Morgan | Overweight |
| 2019-11-04 | 개시 | SVB Leerink | Outperform |
| 2019-11-04 | 개시 | UBS | Buy |
모두보기
바이오앤테크 주식(BNTX)의 최신 뉴스
Under a trading plan, Xin Gao Group buys 6,000 Uxin (UXIN) depositary shares. - Stock Titan
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer - GlobeNewswire Inc.
BioNTech und DualityBio geben Topline-Ergebnisse der globalen klinischen Phase-3-Studie DYNASTY-Breast02 für Trastuzumab Pamirtecan bei metastasiertem HR+/HER2-low-Brustkrebs bekannt - GlobeNewswire Inc.
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy - GlobeNewswire Inc.
BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie - GlobeNewswire Inc.
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports - The Motley Fool
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? - The Motley Fool
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline - The Motley Fool
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX) - Morningstar
Europe’s ADRs Inched Higher As WPP And BP Led - Finimize
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell? - Zacks Investment Research
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? - Zacks Investment Research
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care - GlobeNewswire Inc.
BNTX Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Edge HigherEPS Surprise History - https://www.dars.gov.et/
BNTX Q2 2026 Earnings: Wider-Than-Expected Loss, Yet Shares Edge HigherNet Income Trends - https://www.dars.gov.et/
European ADRs Slip As Ericsson And Nokia Lead Declines - Finimize
BioNTech SE stock gains as Berenberg lifts price target after recent pullback - AD HOC NEWS
BioNTech stock heads into the open after a 2.9 percent Nasdaq drop - AD HOC NEWS
BioNTech Lung Cancer Drug Lifts Survival Versus Chemotherapy - Bloomberg.com
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit? - TradingView
BioNTech's Downsizing Signal: Factory Divestitures and a Trimmed Forecast Frame the Pipeline Debate - aktiencheck.de
BioNTech CEO Ugur Sahin Executes Sale of 76,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Why Pfizer Stock Was so Healthy in August - The Motley Fool
Advanced Micro Devices Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Why is BioNTech stock sliding today? - investing.com
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech's Balancing Act: A COVID Lifeline Arrives Just as Oncology Investors Need a Reason to Stay - aktiencheck.de
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last? - easternprogress.com
BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test () - aktiencheck.de
BioNTech's September Test: Can Oncology Data Outweigh a Shrinking COVID Franchise? () - aktiencheck.de
BioNTech SEADR (BNTX) Fundamental & Financial Data - Stocktwits
BioNTech (NASDAQ: BNTX) investor moves to sell shares; filing shows how big - Stock Titan
BioNTech's Seoul Moment: Why One Halted Trial Hasn't Derailed the Oncology Narrative () - aktiencheck.de
BioNTech's September Crossroads: Seoul Data Readouts and Factory Decisions Will Test the Post-Trial Narrative - aktiencheck.de
BioNTech's Two-Front Battle: Legal Overhang in Europe Meets a Pivotal September for Oncology Data - aktiencheck.de
BNTX stock reacts to halted cancer trial and lower 2026 guidance - AD HOC NEWS
Zacks Investment ResearchGlobes - Globes - Israel Business News
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down - Eastern Progress
BioNTech's Leadership Exodus Looms as Vaccine Franchise Holds While Oncology Ambitions Take a Hit - aktiencheck.de
BioNTech's Split-Screen Week: A Trial Halted, a Vaccine Approved, and a Pipeline Under the Microscope - aktiencheck.de
BioNTech SEADR Peer Comparison – Compare with Others - Value Research
Why is BioNTech stock down 7.8% today? - tradersunion.com
BioNTech SEADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
BioNTech SEADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
BioNTech stock tumbles 10% on cancer trial termination - Investing.com
바이오앤테크 (BNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오앤테크 주식 (BNTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sahin Ugur | Chief Executive Officer |
Oct 08 '26 |
Sale |
92.31 |
27,000 |
2,492,483 |
36,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 07 '26 |
Sale |
95.86 |
24,000 |
2,300,633 |
63,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 06 '26 |
Sale |
96.81 |
21,000 |
2,032,995 |
87,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 05 '26 |
Sale |
97.23 |
72,000 |
7,000,646 |
108,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 02 '26 |
Sale |
96.72 |
17,000 |
1,644,323 |
180,209 |
| Sahin Ugur | Chief Executive Officer |
Oct 01 '26 |
Sale |
97.46 |
17,000 |
1,656,745 |
197,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 30 '26 |
Sale |
98.12 |
32,000 |
3,139,850 |
214,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 29 '26 |
Sale |
98.26 |
34,000 |
3,340,809 |
246,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 28 '26 |
Sale |
98.47 |
34,000 |
3,347,919 |
280,209 |
| Sahin Ugur | Chief Executive Officer |
Sep 25 '26 |
Sale |
98.69 |
27,000 |
2,664,581 |
314,209 |
1.75%
0.03%
자본화:
|
볼륨(24시간):